{"id":"W2129448596","doi":"10.1016/j.neurobiolaging.2015.09.018","title":"MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials","year":2015,"lang":"en","type":"article","venue":"Neurobiology of Aging","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; University of California; National Institutes of Health; Genentech; IXICO; Servier; Eisai; Northern California Institute for Research and Education; University of California, San Diego; DoD Alzheimer's Disease Neuroimaging Initiative; Pfizer; Biogen; BioClinica; F. Hoffmann-La Roche; Synarc; University of Southern California; Medpace; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; Alzheimer's Association","keywords":"Neuroimaging; Magnetic resonance imaging; Atrophy; Cohort; Medicine; Statistical power; Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Positron emission tomography; Biomarker; Clinical trial; Sample size determination; Nuclear medicine; Internal medicine; Psychology; Disease; Radiology; Psychiatry; Statistics; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3067814,0.001906233,0.005394102,0.001915512,0.001098688,0.004089409,0.00258527,0.002946349,0.002607058],"category_scores_gemma":[0.3352181,0.001524316,0.004396454,0.002943147,0.002077483,0.003346509,0.002165366,0.002866043,0.0008148503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001315863,"about_ca_system_score_gemma":0.004569036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007362542,"about_ca_topic_score_gemma":0.001534802,"domain_scores_codex":[0.6342931,0.3393537,0.01220922,0.00537255,0.007424694,0.001346691],"domain_scores_gemma":[0.7854237,0.1671156,0.01554679,0.01868217,0.01133736,0.001894361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2600795,0.00310551,0.1838968,0.01219363,0.02781906,0.001169061,0.002412819,0.04197101,0.0104128,0.01829379,0.01663761,0.4220084],"study_design_scores_gemma":[0.1312847,0.08521631,0.2520312,0.004716801,0.02268097,0.002151603,0.0009849176,0.3207313,0.01871121,0.07263768,0.08814433,0.0007089727],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.3734102,0.03242599,0.4602877,0.01288486,0.002706171,0.09531721,0.004066233,0.002220405,0.01668132],"genre_scores_gemma":[0.6323177,0.001509514,0.2925538,0.002400208,0.000610036,0.06732126,0.001239064,0.0002753463,0.00177299],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.3067814,"threshold_uncertainty_score":0.8548619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3361830784574369,"score_gpt":0.521550541137829,"score_spread":0.1853674626803921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}